Nanoparticles as a Therapeutic Delivery System for Skin Cancer Prevention and Treatment

JID Innovations, Journal Year: 2023, Volume and Issue: 3(4), P. 100197 - 100197

Published: March 16, 2023

The use of nanoparticles (NPs) as a therapeutic delivery system has expanded markedly over the past decade, particularly regarding applications targeting skin. NP-based therapeutics to skin requires special consideration owing its role both physical and immunologic barrier, specific technologies must not only take into target but also pathway delivery. unique challenge this poses been met with development wide panel meant precisely address these considerations. In review article, we describe application for drug skin, summarize types NPs, discuss current landscape NPs cancer prevention treatment well future directions within applications.

Language: Английский

---

Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges

Pharmaceutics, Journal Year: 2022, Volume and Issue: 14(5), P. 1066 - 1066

Published: May 16, 2022

To prevent the coronavirus disease 2019 (COVID-19) pandemic and aid restoration to prepandemic normality, global mass vaccination is urgently needed. Inducing herd immunity through has proven be a highly effective strategy for preventing spread of many infectious diseases, which protects most vulnerable population groups that are unable develop immunity, such as people with immunodeficiencies or weakened immune systems due underlying medical debilitating conditions. In achieving outreach, maintenance vaccine potency, transportation, needle waste generation become major issues. Moreover, phobia hesitancy act hurdles successful vaccination. The use dissolvable microneedles COVID-19 could paradigm shift in attaining desired goal vaccinate billions shortest time possible. addressing these points, we discuss potential based on current literature.

Language: Английский

---

Probiotics as multifaceted oral vaccines against colon cancer: A review

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Oct. 3, 2022

Probiotics are known as the live microorganisms that, upon adequate administration, elicit a health beneficial response inside host. The probiotics immunomodulators and exhibit anti-tumor properties. Advanced research has explored potential use of oral vaccines without latent risks pathogenicity. Probiotic-based to induce mucosal immunity that prevents host from several enteric infections. Probiotic bacteria have ability produce metabolites in form anti-inflammatory cytokines, which play an important role prevention carcinogenesis activation phagocytes eliminate preliminary stage cancer cells. This review discusses advantages disadvantages using probiotic well mechanism action colon therapy. also employs “PROBIO” database for selecting certain with immunomodulatory Furthermore, anti-colon adjuvants been discussed detail. Because current studies trials more focused on attenuated pathogens instead probiotic-based vaccines, future must involve advanced exploiting strains therapies.

Language: Английский

---

Immunogenicity, safety, usability and acceptability of microarray patches for vaccination: a systematic review and meta-analysis

BMJ Global Health, Journal Year: 2023, Volume and Issue: 8(10), P. e012247 - e012247

Published: Oct. 1, 2023

Background Microarray patches (MAPs) deliver vaccines to the epidermis and upper dermis, where abundant immune cells reside. There are several potential benefits using MAPs, including reduced sharps risk, thermostability, no need for reconstitution, tolerability self-administration. We aimed explore evaluate immunogenicity, safety, usability acceptability of MAPs vaccination. Methods searched CINAHL, Cochrane Library, Ovid Embase, MEDLINE Web Science from inception January 2023. Eligibility criteria included all research studies in any language, which examined microarrays or microneedles intended used vaccination explored their findings. Two reviewers conducted title abstract screening, full-text reviewing data extraction. Results Twenty-two were (quantitative=15, qualitative=2 mixed methods=5). The risk bias was mostly low, with two at high bias. Four clinical trials included, three influenza antigens one Japanese encephalitis delivered by MAP. A meta-analysis indicated similar higher immunogenicity compared needle syringe (N&S) (standardised mean difference=10.80, 95% CI: 3.51 18.08, p<0.00001). significant differences cell function between N&S. No serious adverse events reported MAPs. Erythema more common after MAP application than N&S but brief well tolerated. Lower pain scores usually Most found easy use highly acceptable among healthcare professionals, laypeople parents. Conclusion safe tolerated evoked enhanced N&S, further is needed. Vaccine uptake may be increased due less pain, layperson could benefit at-risk groups low middle-income countries. PROSPERO registration number CRD42022323026.

Language: Английский

---

Modification with Conventional Surfactants to Improve a Lipid-Based Ionic-Liquid-Associated Transcutaneous Anticancer Vaccine

Molecules, Journal Year: 2023, Volume and Issue: 28(7), P. 2969 - 2969

Published: March 27, 2023

Transcutaneous vaccination is one of the successful, affordable, and patient-friendly advanced immunization approaches because presence multiple immune-responsive cell types in skin. However, absence a preferable facilitator, skin's outer layer strong impediment to delivering biologically active foreign particles. Lipid-based biocompatible ionic-liquid-mediated nanodrug carriers represent an expedient distinct strategy permit transdermal drug delivery; with acceptable surfactants, performance formulations might be further enhanced. For this purpose, we formulated lipid-based nanovaccine using conventional (cationic/anionic/nonionic) surfactant loaded antigenic protein immunomodulator its core promote delivery by penetrating skin boosting immunogenic activity. In follow-up investigation, freeze-dry emulsification process was used prepare nanovaccine, delivery, pharmacokinetic parameters, ability activate autoimmune cells tumor microenvironment were studied tumor-budding C57BL/6N mouse model. These analyses performed ELISA, nuclei HE staining, flow cytometry, other biological techniques. The immunomodulator-containing significantly (p < 0.001) increased anticancer immune responses (IgG, IgG1, IgG2, CD8+, CD207+, CD103+ expression) without causing cellular or toxicity. Using nanovaccination approach, it possible create more targeted efficient system for cancer antigens, thereby stimulating stronger response compared aqueous formulations. This lead effective therapeutic preventative outcomes patients cancer.

Language: Английский

---